行情

MDWD

MDWD

Mediwound
NASDAQ

实时行情|Nasdaq Last Sale

1.520
-0.020
-1.30%
交易中 15:25 04/08 EDT
开盘
1.570
昨收
1.540
最高
1.570
最低
1.520
成交量
2.93万
成交额
--
52周最高
5.73
52周最低
1.443
市值
4,134.82万
市盈率(TTM)
20.00
分时
5日
1月
3月
1年
5年

分析师评级

5位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测MDWD价格均价为7.10,最高价位10.00,最低价为5.50。

EPS

MDWD 新闻

更多
  • The Daily Biotech Pulse: Fate Therapeutics Inks Cell Therapy Deal With J&J, Zentalis IPO
  • Benzinga · 5天前
  • MediWound Provides Corporate Update Related to COVID-19 Pandemic
  • GlobeNewswire · 03/30 12:30
  • Covid-19 activity roundup - healthcare
  • Seeking Alpha - Article · 03/30 11:48
  • 108 Biggest Movers From Yesterday
  • Benzinga · 03/11 09:34

所属板块

制药
+3.02%
制药与医学研究
+3.02%

热门股票

代码
价格
涨跌幅

MDWD 简况

MediWound Ltd. is a biopharmaceutical company. The Company focuses on developing, manufacturing and commercializing therapeutics products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The Company's product, NexoBrid, is indicated for the removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns, also referred to as severe burns. The Company sells NexoBrid in Europe and Israel. NexoBrid is a topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues. Its product, EscharEx, is a topical biological drug, which is being developed for debridement of chronic and other hard-to-heal wounds. NexoBrid and EscharEx are based on its proteolytic enzyme technology. The Company is also developing an injectable product based on its proteolytic enzyme technology for connective tissue pathologies and indications.
展开

微牛提供Mediwound Ltd(NASDAQ-MDWD)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的MDWD股票新闻,以帮助您做出投资决策。